Guggenheim Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $147

Benzinga · 3d ago
Guggenheim analyst Seamus Fernandez maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $143 to $147.